Lomitapide, a non-statin lipid-lowering agent approved for homozygous familialhypercholesterolemia (hoFH), works by selectively inhibiting MTTP, independent of LDL receptor (LDLR)function. Here, LDLR is linked to homozygous familial hypercholesterolemia.